Reply to intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma

Authors

  • Jeremy S. Abramson MD,

    1. Center for Lymphoma, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts
    2. Department of Medicine, Harvard Medical School, Boston, Massachusetts
    Search for more papers by this author
  • Ephraim P. Hochberg MD

    1. Center for Lymphoma, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts
    2. Department of Medicine, Harvard Medical School, Boston, Massachusetts
    Search for more papers by this author

No abstract is available for this article.

Ancillary